CCL20 and colorectal carcinoma: Finally, given the role of RANKL/RANK signaling in tumorigenesis, anticancer drug clinical trials in the appropriate molecular targets (such as CCL20/CCR6) and RANKL/RANK inhibitors used in combination, or licensing effectively inhibit CRC metastasis, improve treatment effectiveness.